Cambridge, MA, United States of America

Paul Klonowski


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2003-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Paul Klonowski: Innovator in Aggrecanase Research

Introduction

Paul Klonowski is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biomedical research, particularly in the area of aggrecanase and its implications in various diseases. With a total of 2 patents, Klonowski's work is paving the way for advancements in therapeutic applications.

Latest Patents

Klonowski's latest patents focus on human aggrecanase and nucleic acid compositions encoding the same. These patents provide polypeptides related to human aggrecanase, which are useful in a variety of applications, including research, diagnostics, and therapeutic agent screening. The patents also outline methods for inhibiting aggrecanase activity in hosts and treating disease conditions associated with aggrecanase activity, such as rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, and fibrosis.

Career Highlights

Paul Klonowski is currently associated with Syntex (U.S.A.) Inc., where he continues to innovate and contribute to the field of biomedical research. His work has garnered attention for its potential impact on treating various joint and pulmonary diseases.

Collaborations

Klonowski has collaborated with notable colleagues, including John David Allard and Renu Anand Ileller. These collaborations have further enriched his research and development efforts in the field.

Conclusion

In summary, Paul Klonowski is a distinguished inventor whose work on aggrecanase has significant implications for medical research and treatment. His contributions are vital in advancing our understanding and management of diseases associated with aggrecanase activity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…